Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
GraniteShares Advisors LLC Invests $680,000 in Insmed, Inc. $INSM
04:47am, Tuesday, 21'st Apr 2026
GraniteShares Advisors LLC purchased a new position in shares of Insmed, Inc. (NASDAQ: INSM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC
Asset Management One Co. Ltd. Purchases Shares of 80,887 Insmed, Inc. $INSM
03:26am, Tuesday, 21'st Apr 2026
Asset Management One Co. Ltd. acquired a new position in shares of Insmed, Inc. (NASDAQ: INSM) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission
Mirae Asset Global Investments Co. Ltd. Acquires 69,410 Shares of Insmed, Inc. $INSM
05:18am, Monday, 20'th Apr 2026
Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Insmed, Inc. (NASDAQ: INSM) by 764.3% during the undefined quarter, according to its most recent Form 13F filing with the Se
Assetmark Inc. Acquires 4,438 Shares of Insmed, Inc. $INSM
03:39am, Sunday, 19'th Apr 2026
Assetmark Inc. boosted its holdings in Insmed, Inc. (NASDAQ: INSM) by 12.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commis
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on Thursday as mixed re
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure
09:41am, Wednesday, 08'th Apr 2026
INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.
Insmed discontinues development of skin condition drug after mid-stage study miss
04:32pm, Tuesday, 07'th Apr 2026
Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.
Insmed Provides Clinical Update on Phase 2b CEDAR Study
04:01pm, Tuesday, 07'th Apr 2026
—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for E
Park Capital Management LLC WI Invests $1.04 Million in Insmed, Inc. $INSM
06:05am, Monday, 06'th Apr 2026
Park Capital Management LLC WI acquired a new position in Insmed, Inc. (NASDAQ: INSM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange
Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 19,638 Shares of Stock
05:00am, Friday, 03'rd Apr 2026
Insmed, Inc. (NASDAQ: INSM - Get Free Report) insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.
Insmed, Inc. $INSM Shares Sold by Allspring Global Investments Holdings LLC
03:13am, Friday, 03'rd Apr 2026
Allspring Global Investments Holdings LLC lessened its stake in shares of Insmed, Inc. (NASDAQ: INSM) by 3.3% during the undefined quarter, according to the company in its most recent filing with the
Options Bulls Could Be Right About This Pharma Stock
01:05pm, Wednesday, 01'st Apr 2026
Insmed Inc (NASDAQ:INSM) shares were last seen up 0.3% to trade at $164.03, after a price-target hike to $237 from $231 at Barclays.
Insmed: The Pipeline Is Catching Up To The Valuation
07:30am, Wednesday, 01'st Apr 2026
Insmed remains a Buy, with enterprise value near $30B and robust growth driven by Brinsupri and pipeline assets. Brinsupri's launch exceeded expectations, with Q4 revenues of $144.6M and management gu
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?
03:51am, Tuesday, 31'st Mar 2026
Insmed (INSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
E. Ohman J or Asset Management AB Makes New $912,000 Investment in Insmed, Inc. $INSM
05:06am, Thursday, 26'th Mar 2026
E. Ohman J or Asset Management AB purchased a new stake in Insmed, Inc. (NASDAQ: INSM) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchase
